NSCLC
Conditions
Interventions
Observation group:None
Sponsors
The first people's hospital of ziyang
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Eligible participants were adults aged >=18,both men and women; 2.ECOG PS 0-2; 3.Histologically or cytologically con?rmed limiting stage or advanced stage NSCLCESCC; 4.Had no previous systemic chemotherapy; 5.Had at least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1; 6.Had a life expectancy of at least 12 weeks; 7.Vital organ functions meet the following requirements; 8.Human body composition analysis was performed before the first treatment of Camrelizumab; 9.All patients provided written informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with active or untreated CNS metastases by CT/MRI were excluded from the study. 2.Had other malignant tumors or malignant diseases in the three years prior to enrollment; 3.Confirmed or suspected to have interstitial pneumonia, autoimmune diseases, and serious cardiovascular and cerebrovascular diseases; 4.Received any other drug treatment or participated in another clinical study within 4 weeks prior to signing the ICF; 5.Known allergy to Camrelizumab or excipients, known severe allergic reactions to any of the mabs; 6.The researchers determined that other conditions were not suitable for inclusion in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR,Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS,progression-free survival;Safety;OS,Overall survival; | — |
Countries
China
Contacts
Public ContactJieyan Luo
The first people's hospital of ziyang
Outcome results
None listed